ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ALCJ Crossject

2.12
0.01 (0.47%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Crossject EU:ALCJ Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.01 0.47% 2.12 2.09 2.15 2.16 2.07 2.12 53,219 16:30:03

Crossject to present at Biotech Showcase on January 9 at 16:30 PT

09/01/2024 3:21pm

GlobeNewswire Inc.


Crossject (EU:ALCJ)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Crossject Charts.
Crossject to present at Biotech Showcase on January 9 at 16:30 PT

 

Press Release

Crossject to present at Biotech Showcase on January 9 at 16:30 PT

Dijon, France, January 9, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a presentation at the Biotech Showcase conference, being held in San Francisco, on January 9, 2024 at 16:30 PT (January 10, 01:30 CET).

Details of the presentation:

Time: Tuesday, January 9, 2024, 16:30 PT

Track: Yosemite C (Ballroom Level)

Webcast: https://event.webcasts.com/starthere.jsp?ei=1651413&tp_key=8efdfbf518

A webcast replay will be available two hours after the end of the presentation.

About Crossject

Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma companybased in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, anepileptic rescue therapy, for which it was awarded a $60 million contract with the U.S.Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, which is designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

For further information, please contact:

Investors Natasha DrapeauCohesion Bureau+41 76 823 75 27natasha.drapeau@cohesionbureau.com MediaSophie BaumontCohesion Bureau+33 6 27 74 74 49sophie.baumont@cohesionbureau.com 

Attachment

  • Crossject_Press release SF Presentation 09012024

1 Year Crossject Chart

1 Year Crossject Chart

1 Month Crossject Chart

1 Month Crossject Chart

Your Recent History

Delayed Upgrade Clock